Andersons pediatric cardiology 2119
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.89 KB, 3 trang )
Pharmacol.2009;158(3):693–705.
39.HylekEM,Evans-MolinaC,SheaC,Henault
LE,ReganS.Majorhemorrhageandtolerability
ofwarfarininthefirstyearoftherapyamong
elderlypatientswithatrialfibrillation.
Circulation.2007;115(21):2689–2696.
40.JacobsLG.Warfarinpharmacology,clinical
management,andevaluationofhemorrhagicrisk
fortheelderly.ClinGeriatrMed.
2006;22(1):17–32[vii–viii].
41.StreifW,AndrewM,MarzinottoV,etal.
Analysisofwarfarintherapyinpediatric
patients:Aprospectivecohortstudyof319
patients.Blood.1999;94(9):3007–3014.
42.ShehabN,SperlingLS,KeglerSR,BudnitzDS.
Nationalestimatesofemergencydepartment
visitsforhemorrhage-relatedadverseevents
fromclopidogrelplusaspirinandfromwarfarin.
ArchInternMed.2010;170(21):1926–1933.
43.LimdiNA,WadeliusM,CavallariL,etal.
Warfarinpharmacogenetics:asingleVKORC1
polymorphismispredictiveofdoseacross3
racialgroups.Blood.2010;115(18):3827–3834.
44.GageBF,EbyC,JohnsonJA,etal.Useof
pharmacogeneticandclinicalfactorstopredict
thetherapeuticdoseofwarfarin.ClinPharmacol
Ther.2008;84(3):326–331.
45.InternationalWarfarinPharmacogeneticsC,
KleinTE,AltmanRB,etal.Estimationofthe
warfarindosewithclinicalandpharmacogenetic
data.NEnglJMed.2009;360(8):753–764.
46.FinkelmanBS,GageBF,JohnsonJA,Brensinger
CM,KimmelSE.Geneticwarfarindosing:
tablesversusalgorithms.JAmCollCardiol.
2011;57(5):612–618.
47.Nowak-GottlU,DietrichK,SchaffranekD,etal.
Inpediatricpatients,agehasmoreimpacton
dosingofvitaminKantagoniststhanVKORC1
orCYP2C9genotypes.Blood.
2010;116(26):6101–6105.
48.VearSI,AyersGD,VanDriestSL,etal.The
impactofageandCYP2C9andVKORC1
variantsonstablewarfarindoseinthepaediatric
population.BrJHaematol.2014;165(6):832–
835.
49.BissTT,AveryPJ,BrandaoLR,etal.VKORC1
andCYP2C9genotypeandpatient
characteristicsexplainalargeproportionofthe
variabilityinwarfarindoserequirementamong
children.Blood.2012;119(3):868–873.
50.ShawK,AmstutzU,HildebrandC,etal.
VKORC1andCYP2C9genotypesarepredictors
ofwarfarin-relatedoutcomesinchildren.Pediatr
BloodCancer.2014;61(6):1055–1062.
51.HambergAK,WadeliusM.Pharmacogeneticsbasedwarfarindosinginchildren.
Pharmacogenomics.2014;15(3):361–374.
52.MoreauC,BajolleF,SiguretV,etal.VitaminK
antagonistsinchildrenwithheartdisease:height
andVKORC1genotypearethemain
determinantsofthewarfarindoserequirement.
Blood.2012;119(3):861–867.
53.MarekE,MomperJD,HinesRN,etal.
Predictionofwarfarindoseinpediatricpatients:
anevaluationofthepredictiveperformanceof
severalmodels.JPediatrPharmacolTher.
2016;21(3):224–232.
54.KazuiM,NishiyaY,IshizukaT,etal.
IdentificationofthehumancytochromeP450
enzymesinvolvedinthetwooxidativestepsin
thebioactivationofclopidogreltoits
pharmacologicallyactivemetabolite.Drug
MetabDispos.2010;38(1):92–99.
55.DansettePM,RosiJ,BerthoG,MansuyD.
CytochromesP450catalyzebothstepsofthe
majorpathwayofclopidogrelbioactivation,
whereasparaoxonasecatalyzestheformationof
aminorthiolmetaboliteisomer.ChemRes
Toxicol.2012;25(2):348–356.
56.BrandtJT,CloseSL,IturriaSJ,etal.Common
polymorphismsofCYP2C19andCYP2C9
